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This study examined the use of potentially inappropriate medicines that may affect cognition 
(PIMcog) in people with dementia and its associated factors. Medical records of all out-patients with 
dementia attending a tertiary hospital in Vietnam between 1st, Jan 2015 and 31st, Dec 2016 were 
examined. Medicine use was assessed against a list of PIMcog. Variables associated with having a 
PIMcog were assessed using a multiple logistic regression. Of the 128 patients, 41% used a PIMcog, 
39.1% used CEIs concomitantly with anticholinergics, and 18% used antipsychotics. Number of 
hospital visits (adjusted OR 1.08; 95% CI 1.02 – 1.16) and number of treating specialists (adjusted 
OR 0.61; 95% CI 0.45 – 0.83) were associated with PIMcog use. This study highlights a high level 
use of medicines that can further impair cognition or reduce the effectiveness of CEIs in people with 
dementia.  Efforts to improve quality use of medicines for this population are warranted. 
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Dementia is a costly health condition that has a significant impact on individuals, their family 
caregivers, communities and society.1 By 2018, dementia will become a trillion US dollar disease and 
the cost continues to rise to USD 2 trillion by 2030.1 Already being the home of nearly 60% of people 
with dementia worldwide, compared to high income countries, low and middle income countries 
(LMICs) are facing a much more rapid growth in numbers of people with dementia1 often without a 
well-developed or well-funded healthcare system, resulting in lack of diagnosis and poor quality 
treatment  for  people with dementia.2 Not an exception, Vietnam with a projected increase from 10% 
in 2015 to 28% in 2050 in the proportion of its population aged 60 years and above3 and an estimated 
dementia prevalence ranging from 4.2% to 7.9% in these elderly4,5 may have as many as 2.4 million 
people living with dementia by the mid-21st century. 
Most people living with dementia are older,6 thus likely to have multiple chronic conditions and 
taking multiple medicines7 with the associated increased risk of adverse drug reactions due to drug 
interactions and due to altered pharmacokinetic and pharmacodynamic profiles in older persons.8  
These issues can confound dementia management where multiple medicine use and aging make 
individuals more sensitive to the effects of medicines on cognition.9,10 Lack of evidence from 
randomised controlled trials for the use of medicines in people with dementia because of their 
exclusion in most clinical trials further compounds the problems of medicine use in this 
population.11,12  
In the absence of preventive or curative treatments of dementia, current pharmacological therapies 
focus on modifying symptoms of cognitive impairment (e.g. using anti-dementia medicines such as 
cholinesterase inhibitors  - CEIs or memantine), managing behavioural and psychological symptoms 
of dementia (BPSD) and managing cardiovascular and cardio-metabolic symptoms, which if not 
managed would make dementia worse. Other management strategies focus on maintaining cognition. 
For this reasons, medicines with anticholinergic or sedative effects should be avoided where possible 
in persons with dementia due to the association between these medicines and cognitive decline.9,13,14 
Further, anticholinergic medicines have the potential to antagonise the effect of CEIs, the medicines 
to treat symptoms of dementia.15 Among anticholinergic and sedative medicines, antipsychotics are 
often used to manage BPSD. However, they have limited efficacy16 and can be successfully de-
prescribed.17  
Different factors have been reported to be associated with inappropriate medication use.18-21 They can 
be categorised into system and environmental factors (e.g. residential aged care structure),22 physician 
and health professional related factors (e.g. diagnostic and therapeutic knowledge and skills, 
prescribing culture)23 or patient related factors (e.g. age, gender, education or socioeconomic status, 
comorbidity or number of medicines prescribed).24,25 Little is known about the quality use of 
medicines in people with dementia in Vietnam and its associated factors. This study was conducted to 
examine the prevalence of potentially inappropriate medication use for people with dementia, with a 
focus on those that affect cognition (PIMcog) and to analyse potential variables associated with 
having a PIMcog to provide evidence-based information for subsequent programs supporting quality 
use of medicines in dementia care in Vietnam. We also examined the prevalence of concomitant use 
of CEIs and anticholinergics, as well as the appropriateness of selection, initiation dosing and the 
length of use of antipsychotics in people with dementia in Vietnam. 
Methods 
Data source and study design 
The National Geriatric Hospital (NGH) is the leading tertiary hospital in Vietnam taking care of 
geriatric patients. In 2008 the hospital started its national program on “Management, care and 
treatment of people with dementia”. Patients referred to NGH for cognitive impairment have a 
thorough medical review, including medical history, assessment of mental status and mood testing, 
physical and neurological examination and tests to rule out other causes of dementia-like symptoms. 
Patients diagnosed with dementia are included in the hospital’s dementia program and are requested 
to visit every month for check-up and medicine dispensing, which is subsidised under a special 
insurance program. A database of these patients has been established and data since January 2015 
have been computerised. 
Analyses of medicine use in all out-patients with dementia attending NGH were conducted for the 
period 1st, Jan 2015 to 31st, Dec 2016. Medical records and prescriptions of all patients diagnosed with 
dementia during the study period were examined. The medical record contains information on 
patients’ demographics, diagnosis of dementia, cognitive function test (e.g. MMSE score), other 
comorbidities and prescribing information (medicine name, strength, dosage, quantity and route of 
administration). Health service characteristics were recorded, including the specialty of prescribers.  
Medicines included in analyses 
Data were collected using a data collection form developed in a macro enabled excel spreadsheet. 
Medicines were coded according to the World Health Organization’s Anatomical Therapeutic 
Chemical (ATC) classification system.26 Anti-dementia medicines included in the analysis were 
donepezil (N06DA02), rivastigmine (N06DA03) and galantamine (N06DA04). Memantine 
(N06DX01) was not available in the Vietnam market. A master list of all medicines used in people 
with dementia at the hospital during the study period was established. The medicines on this list were 
first assessed against a PIMcog list24 - Vietnamese modification, which contained individual 
medicines available in Vietnam considered potentially inappropriate for use in older people with 
cognitive impairment (Appendix 1) and developed based on Beers 2012 criteria27 and STOPP 2014 
criteria28 but limited to those medicines that are related to cognitive impairment.24 Second, 
concomitant use of CEIs with anticholinergic medicines was assessed using a list of medicines 
available in Vietnam with clinically relevant anticholinergic and sedative properties (Appendix 2) 
following a previously published approach29,30 and based on a consensus combination of different 
anticholinergic scales.31 Concomitant use was defined where co-prescribing of ECIs with 
anticholinergic agents was recorded at the same hospital visit. Medicines accounting for the difference 
between the PIMcog list and the list of medicines with anticholinergic or sedative effects are 
presented in Appendix 3.  
A list of antipsychotics used by study participants was also compiled. Incident use of antipsychotics 
was defined as prescribing antipsychotics after no prescription of antipsychotics was recorded at any 
of the previous three monthly hospital visits. Continuous use of antipsychotics was defined as 
prescribing antipsychotics at consecutive monthly hospital visits. Information on type, initial and 
maximum doses, as well as duration of antipsychotics continuously prescribed were collected and 
assessed against the Australia’s dementia care guidelines16 and Australian Medicines Handbook.32 
These references were used in the absence of Vietnam’s dementia care guidelines. In Australia, 
risperidone is the only antipsychotic medicine subsidised for treatment  of BPSD resistant to non-
pharmacological measures in Alzheimer-type moderate-to-severe-dementia (for up to 12 weeks), with 
an initial dose of 0.25mg twice daily, increasing by 0.25mg daily every two or more days if necessary 
to a maximum dose of 2mg per day.32 
Statistical analyses 
Descriptive statistics were used to describe the demographics and medicine use in the dementia 
population, including the proportion of patients who used at least one medicine on the PIMcog list, 
who used CEIs with anticholinergic medicines concomitantly or who used at least one antipsychotic 
medicine during the study period. The median number of unique medicines used by individual 
patients across hospital visits was calculated and the median of median value across patients was 
reported. Multiple logistic regressions were conducted to assess the association of different variables 
and having a PIMcog, including age, gender, type of dementia, severity of dementia, number of co-
morbidities, number of medicines used other than PIMcog, number of hospital visits and number of 
treating specialists. Missing data were imputed using the fully conditional method in a multiple 
imputation approach.33 All analyses were performed using the SAS 9.4 statistical package (SAS 
Institute, Cary, NC, USA). 
Results 
Participant characteristics 
Data were retrieved from 128 patients who participated in the national program on “Management, 
care and treatment of people with dementia” at some time during the study period (Table 1). The 
mean age (Standard deviation - SD) of the participants at the first hospital visit for dementia treatment 
during the study period was 71.9 years (11.0). Sixty four (50%) patients had at least one comorbidity 
and 32 (25%) had two or more comorbidities. The most common comorbidities include hypertension 
(n = 30, 23.4%), hyperlipidemia (n = 24, 18.8%) and diabetes (n = 12, 9.4%).  
Table 1 is about here 
General use of medicines and anti-dementia medications 
Half of the participants were prescribed between two and four medicines per hospital visit (Table 2) 
and 18 (14.1%) patients had a median of five or more medicines prescribed per visit.  
Throughout the study period, the most commonly used medicines included CEIs and ginkgobiloba. In 
total, 122 (95.3%) patients used medicines considered to improve cognitive function at some time 
during the study period, of whom 115 (89.8%) patients used CEIs and 77 (60.2%) used ginkgobiloba 
products. Among 115 patients who were prescribed CEIs, 94 patients (81.7%) had these medicines 
prescribed continuously for more than six months and 31 patients (27.0%) were at a severe stage of 
dementia. CEIs being prescribed to patients were galantamine (n = 109, 85.2%), rivastigmin (n = 23, 
18.0%) and donepezil (n = 11, 8.6%). 
Other medicines commonly prescribed were vitamins, e.g. vitamin E (n = 86, 67.2%), vitamin B1 (n = 
63, 49.2%), vitamin B6 (n = 47, 36.7%), and vitamin B12 (n = 45, 35.2%). The use of diazepam (n = 
42, 32.8%) and piracetam (n = 31, 24.2%) was also frequently observed. 
Table 2 is about here 
Use of PIMcogs  
Fifty three patients (41.4%) were prescribed at least one PIMcog at some time during the study 
period. Three patients were prescribed two or more PIMcog concomitantly at the same visit on at least 
one occasion in the two year period (Table 2). Similar figures were observed when assessing the 
PIMcog use in study participants aged 65 years or above only (data not shown).  
The most commonly used classes of PIMcog were sedatives (e.g. benzodiazepines – n = 42; non-
benzodiazepine hypnotic – n = 1) and anticholinergics (e.g. tricyclic antidepressants – n = 10; 
antiparkinson agents – n = 5; antipsychotics – n = 2). The most commonly used individual PIMcogs 
were diazepam (n = 42), amitriptyline (n = 10) and trihexyphenidyl (n = 5). 
Our initial multiple logistic regression model consisted of the following variables: age, gender, type of 
dementia, severity of dementia recorded by treating doctors, number of co-morbidities, median 
number of medicines other than PIMcog used per hospital visit, number of hospital visits and number 
of treating specialists. The backward elimination using a significance level of 0.2 to retain variables in 
the model resulted in a final model, which contained the following variables: gender, age, number of 
hospital visits and number of treating specialists. The final logistic regression model indicated that a 
higher number of hospital visits during the study period (adjusted OR 1.08; 95% CI 1.02 – 1.16) was 
positively associated with PIMcog use.  By contrast, higher number of treating specialists (adjusted 
OR 0.61; 95% CI 0.45 – 0.83) was negatively associated with PIMcog use. No statistically significant 
associations between older age (adjusted OR 1.02; 95% CI 0.99 – 1.06) or female gender (adjusted 
OR 1.55; 95% CI 0.72 – 3.30) and PIMcog use were found. 
Concomitant use of CEIs with anticholinergics 
Seventy eight patients (60.9%) were prescribed at least one medicine with sedative or anticholinergic 
effects at some time during the study period. Excluding those using medicines with sedative effect 
only, 66 (51.6%) patients were prescribed at least one anticholinergic medicine at some time during 
the study period. Fifty patients concurrently used an anticholinergic agent with CEIs, accounting for 
39.1% of all 128 patients or 43.5% of 115 patients who were using CEIs. 
Antipsychotics use 
Twenty three (18.0%) patients were prescribed at least one antipsychotic medicine at some time 
during the study period. Sixteen patients (12.5%) were concomitantly prescribed antipsychotic 
medicines with CEIs. Antipsychotic medicines most commonly used were sulpiride (n = 9), followed 
by risperidone (n = 8), quetiapine (n = 8), clozapine (n = 1) and olanzapine (n = 1). Ten patients 
initiated antipsychotics during the study period and 13 patients were prescribed antipsychotics within 
their first three hospital visits. Six patients used antipsychotics continuously for more than three 
months.  
Among eight patients who used risperidone, three patients initiated risperidone during the study 
period, all of whom had their initial dose of more than 0.5mg/day; one with an initial dose of 
2.0mg/day and two with 1.0mg/day. 
Discussion 
Our results show that potentially inappropriate medicine use is common in patients with dementia 
attending a tertiary hospital in Vietnam. Forty one percent of patients used at least one medicine 
considered potentially inappropriate for use in older people with cognitive impairment, while 39.1% 
used CEIs together with an anticholinergic agent. Eighteen percent of patients were prescribed 
antipsychotics, of whom a quarter used the medicines continuously for more than three months. Of 
those who initiated risperidone, the initial dose of risperidone was not optimal in treatment of BPSD. 
These findings are not unique to Vietnam. Studies in developed countries have shown that 
anticholinergic and sedative medicines have been frequently prescribed in people with dementia or 
concurrently used with CEIs although the extent might vary.24,29,34-36 PIMcog use was reported among 
21.4% of patients with dementia attending memory clinics in Australia, with anticholinergics and 
sedatives being the most common classes of PIMcog.24 In our study, these two classes were also the 
most frequent among PIMcog with benzodiazepines (e.g. diazepam), which have both sedative and 
anticholinergic properties, topping the list.  The prevalence of PIMcog in our study (41%), however, 
almost doubles the number in the Australian study. 24 One possible explanation for this difference is 
the different designs of the studies. In our study, we looked at all prescriptions at repeated hospital 
visits of individual patients during the study period of two years whereas the Australian study only 
looked at medication exposure of individual patients at one time point of recruitment.24 Another 
possibility is the difference in the quality of health service delivery between a high income country 
and a LMIC with LMICs having been reported to have a more severe problem of inappropriate 
medication use.37 
In the US, 37% of CEI users received anticholinergics,34 which is similar to the finding in our study 
(39.1%). A study on the use of antipsychotics among people with dementia in Australian residential 
aged care facilities showed that 44% of patients with dementia received antipsychotics concomitantly 
with anti-dementia medicines at some time during the study period, of the subset who initiated 
antipsychotics 53% used antipsychotics continuously for more than six months and 43% had 
suboptimal initial doses of risperidone.38 The institutional setting of residential aged care facilities 
might explain the higher prevalence of antipsychotic use in the Australian study compared to that in 
our study of community-dwelling outpatients (18.0%).39,40  A prevalence of antipsychotic use of 
12.8% and 25.3% (18.1% overall) was reported for people with dementia in non-institutional and 
institutional settings, respectively in Sweden,40 and up to 25% of people with dementia in the UK 
were estimated to be on antipsychotics at any time.41 
Our results show anti-dementia medicines used to boost cognitive function in people with dementia in 
Vietnam included CEIs and ginkgobiloba. More than 95% of patients were prescribed at least one 
anti-dementia medicine, of which 89.8% were prescribed a CEI and 60.2% were prescribed 
ginkgobiloba products. CEIs and ginkgobiloba have a modest efficacy if any in dementia and 
cognitive impairment,42,43 and conflicting evidence or no long-term efficacy (more than 6 months).44,45 
CEIs have been associated with a number of adverse reactions (e.g. bradycardia and syncope).44 
Ginkgobiloba has a better safety profile43,46 but cerebral bleeding and prolonged bleeding have been 
reported to be associated with ginkgobiloba use, and this may be intensified with use of 
antidepressants,47 a common medicine class used by people with dementia.40 The anti-dementia 
medicines therefore should be considered for de-prescribing when patient’s dementia has progressed 
to a severe stage.44 Among patients who were prescribed CEIs in this study, 81.7% had these 
medicines prescribed continuously for more than six months and 27.0% were at a severe stage of 
dementia. Periodical review taking into account both perceived benefits and adverse effects to 
consider stopping anti-dementia medicines is recommended.16 
More than two in five patients with dementia in our study used a PIMcog. We found that PIMcog use 
was positively associated with a higher number of hospital visits. Interestingly, a higher number of 
treating specialists, who were all neurologists, were found negatively associated with PIMcog use. A 
possible explanation is that seeing different providers creates a check and balance system that helps to 
reduce the discretion of individual physicians in prescribing. However, further exploration is 
warranted to understand the rationale behind the prescribing practices of medical specialists for 
people with dementia in Vietnam. 
In this study we also looked at the use of all PIMs with sedative and anticholinergic properties. 
Anticholinergics have been known to be associated with cognitive decline9,13,14 and might reduce the 
efficacy of CEIs due to an antagonistic mechanism.9,15 Apart from worsening cognitive impairment 48, 
sedatives also increase the risk of falls.49 People with dementia have impaired cognition and are 
vulnerable to falling,50 thus should not be prescribed sedatives and anticholinergics where possible. 
Nearly 61% of our participants were prescribed sedatives and anticholinergics during the study period 
and almost 40% used CEIs and anticholinergics concomitantly.  
Eighteen percent of our patients used antipsychotics for the management of BPSD. Sulpiride was the 
most commonly used antipsychotic, which may not be ideal because sulpiride has been found to be 
associated with an increased risk of extrapyramidal symptoms at a similar level to haloperidol.51 
Risperidone might be a better option as it is considered the best evidenced treatment of BPSD.52-54 
Nevertheless, due to modest efficacy and poor tolerability53,55 as well as association with stroke,56 hip 
fracture and pneumonia,57 a poorer quality of life58 and increased mortality59 of antipsychotics , these 
medicines should only be used as a last resort to manage severe BPSD with low initial dose and 
regular review every one to three months for de-prescribing.16  
Our study had some limitations. Firstly, we only examined the use of medicines in patients with 
dementia attending one tertiary teaching hospital in Vietnam and these patients were in a national 
program on “Management, care and treatment of people with dementia”. The pattern of medicine use 
in people with dementia in our study therefore only reflects the prescribing practice within the 
teaching hospital. There is a special insurance cap that limits the total cost of medicines per 
prescription for patients in this program and this is likely to affect the prescribing practice. In 
addition, our sample is quite small and of one ethnicity only. While these shortcomings limit the 
generalisation of our findings to dementia treatment in Vietnam and to other samples, particularly 
those in high-income countries, our study has identified the scope for improvement in prescribing 
practice for people with dementia at a tertiary teaching hospital level. 
Secondly, PIMcog list was developed based on Beers and STOPP criteria which are for patients aged 
65 years or over and 24.2% of our patients aged less than 65 years. However, while reporting the 
prevalence of PIMcog use for all study participants, this prevalence was similar to the PIMcog use 
prevalence assessed in the subgroup of patients aged 65 years or over only. We also examined the use 
of medicines against a list of medicines with anticholinergic and sedative effects, which should be 
avoided in people with dementia because of their potential adverse effects including but not limited to 
cognitive impairment. Several scales have been developed for screening anticholinergic medications 
but considerable variation exists across those scales.31 Using a uniform list of anticholinergic 
medicines developed based on consensus on the clinical relevance of alleged anticholinergic 
properties among different scales in addition to sedative medicines for screening PIMs with 
anticholinergic and sedative effect can be considered as strength of our study. 
In conclusion, PIMcog use, anticholinergics and sedatives use, and concurrent use of CEIs with 
anticholinergics were prevalent in patients in the Vietnam national dementia care program. The use of 
antipsychotic medicines seemed suboptimal from the selection of antipsychotic products to the 
initiation dosing to the treatment duration. Further research exploring the rationale behind the current 
prescribing practice and interventions such as pharmacist medicine review, clinical audits and targeted 
de-prescribing is needed to improve quality use of medicines and health outcomes of people with 
dementia in Vietnam. 
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Table 1: Participants’ demographic characteristics 
Characteristic Participants [n = 128] 
 
Age at the first hospital visit for dementia treatment during the study period [years; 
mean (SD)]* 
71.9 (11.0) 
     Less than 65 years [n (%)] 31 (24.2%) 
     Between 65 and 79 years [n (%)] 75 (58.6%) 
     80 years or above [n (%)] 22 (17.2%) 
Female gender [n (%)] 66 (51.6%) 
Diagnoses  
     Alzheimer’s dementia [n (%)] 103 (80.5%) 
     Vascular dementia [n (%)] 19 (14.8%) 
     Mixed dementia [n (%)] 6 (4.7%) 
MMSE score [median ((IQR)]† at the last hospital visit 18 (11-23) (n = 93, 
missing data from 35 
patients). 
Severity of dementia recorded by treating specialists  
     Mild 39 (30.5%) 
     Moderate 33 (25.8%) 
     Advanced 32 (25.0%) 
     Missing 24 (18.7%) 
Number of co-morbidities [median (IQR)] ‡  0.5(0-1.5) 
Number of dementia treating specialists [median (IQR)] ‡ 4 (3-5) 
 
* SD standard deviation 
† IQR interquartile range,  
‡ Values for the study period of two years 
Table 2: Medicine use 
Features Participants [n = 128] 
 
General use  
     Number of unique medicines prescribed per hospital visit [median (IQR)*]† 2.25 (2-4) 
     Number of unique medicines prescribed per patient in the two year period 
[median (IQR)]  
8 (6-11) 
     Prescribing of ginkgobiloba products at any time in the two year period [n (%)] 77 (60.2%) 
     Prescribing of CEIs‡ at any time in the two year period [n (%)] 115 (89.8%) 
PIMcog use  
     Prescribing of at least one PIMcog§ at any time in the two year period [n (%)] 53 (41.4%) 
     Prescribing of two or more PIMcogs concomitantly at the same visit on at least 
one hospital visit in the two year period [n (%)] 
3 (2.3%) 
Co-prescribing of CEIs with anticholinergics at the same visit on at least one 
occasion in the two year period [n (%)] 
50 (39.1%) 
Antipsychotics use  
     Prescribing of at least one antipsychotic medicine at any time in the two year 
period [n (%)] 
23 (18.0%) 
     Continuous prescribing of antipsychotics for more than three months [n (%)] 6 (4.7%) 
     Co-prescribing of antipsychotics with CEIs at the same visit on at least one 
occasion in the two year period [n (%)] 
16 (12.5%) 
 
* IQR interquartile range 
† The median number of unique medicines prescribed for individual patients across hospital visits was first 
calculated and the median of median values across patients was reported. 
‡ CEIs cholinesterase inhibitors. 
§ PIMcog potentially inappropriate medicine for people with cognitive impairment.  
 
Appendix 1: Potentially inappropriate medicines related to cognitive impairment (PIMcog) 24 in 
Vietnam 
Group Name ATC 
Antipsychotics Chlorpromazine N05AA01 
 Clozapine N05AH02 
 Loxapine N05AH01 
 Olanzapine N05AH03 
Tricyclic antidepressants  Amitriptyline N06AA09 
Antimuscarinics (urinary) Flavoxate G04BD02 
 Oxybutynin G04BD04 
Antispasmodics Atropine products A03BA01 
 Hyoscyamine products A03BA03 
 Loperamide A07DA03 
First generation antihistamines  Brompheniramine R06AB01 
 Chlorpheniramine R06AB04 
 Dexbrompheniramine R06AB06 
 Dexchlorpheniramine R06AB02 
 Diphenhydramine R06AA02 
 Hydroxyzine N05BB01 
 Promethazine R06AD02 
 Triprolidine R06AX07 
Other antihistamines (with anticholinergic 
properties) Dimenhydrinate R06AA52 
 Loratadine R06AX13 
Antiparkinson agents Trihexyphenidyl (benzhexol) N04AA01 
Benzodiazepines (BZD) Diazepam N05BA01 
 Midazolam N05CD08 
Non-BZD hypnotics Zolpidem N05CF02 
 Zopiclone N05CF01 
Barbiturates Phenobarbital (Phenobarbitone) N03AA02 
Systemic corticosteroids Betamethasone H02AB01 
 Betamethasone R03BA04 
 Dexamethasone H02AB02 
 Hydrocortisone H02AB09 
 Methylprednisolone H02AB04 
 Prednisolone/prednisone H02AB06 
 Triamcinolone H02AB08 
Histamine-2 receptor antagonists  Cimetidine A02BA01 
 Famotidine A02BA03 
 Ranitidine A02BA02 
Appendix 2: Medicines with anticholinergic and sedative properties 29,31 in Vietnam 
Group Name ATC Effect 
H2 antagonists Cimetidine A02BA01 A1 
H2 antagonists Ranitidine A02BA02 A1 
GI disorder Dicyclomine A03AA07 A2 
GI disorder Atropine A03BA01 A2 
GI disorder Domperidone A03FA03 A1 
Intestinal antiinfectives Loperamide A07DA03 A1 
Antihypertensives Methyldopa C02AB01 S 
Urinary incontinence Flavoxate G04BD02 A2 
Urinary incontinence Oxybutynin G04BD04 A2 
NSAID Ketorolac M01AB15 A1 
Muscle relaxants Methocarbamol M03BA03 A1 
Muscle relaxants Baclofen M03BX01 A1,S 
Opioids Morphine N02AA01 A1,S 
Opioids Codeine/paracetamol N02AA59 S 
Opioids Fentanyl N02AB03 A1,S 
Opioids Dextropropoxyphene N02AC04 S 
Opioids Tramadol N02AX02 A1,S 
Antiepileptics Phenobarbital N03AA02 S 
Antiepileptics Phenytoin N03AB02 S 
Antiepileptics Clonazepam N03AE01 A1,S 
Antiepileptics Carbamazepine N03AF01 A1,S 
Antiepileptics Oxcarbazepine N03AF02 A1 
Antiepileptics Valproate N03AG01 S 
Antiepileptics Vigabatrin N03AG04 S 
Antiepileptics Lamotrigine N03AX09 S 
Antiepileptics Topiramate N03AX11 S 
Antiepileptics Gabapentin N03AX12 S 
Antiepileptics Pregabalin N03AX16 S 
Anticholinergic antiparkingson Trihexyphenidyl N04AA01 A2 
Dopaminergic antiparkingson Entacapone N04BX02 A1 
Antipsychotics Chlorpromazine N05AA01 A2,S 
Antipsychotics Levomepromazine N05AA02 A2 
Antipsychotics Haloperidol N05AD01 A1,S 
Antipsychotics Clozapine N05AH02 A2 
Antipsychotics Olanzapine N05AH03 A1,S 
Antipsychotics Quetiapine (fumarate) N05AH04 A1,S 
Antipsychotics Amisulpride N05AL05 S 
Antipsychotics Lithium N05AN01 A1 
Antipsychotics Risperidone N05AX08 A1,S 
Anxiolytics Benzodiazepine Diazepam N05BA01 A1,S 
Anxiolytics Benzodiazepine Chlordiazepoxide N05BA02 A1 
Anxiolytics Benzodiazepine Bromazepam N05BA08 S 
Anxiolytics other Hydroxyzine N05BB01 A2 
Hypnotics Benzodiazepine related Zopiclone N05CF01 S 
Hypnotics Benzodiazepine related Zolpidem N05CF02 S 
Antidepressants  Amitriptyline N06AA09 A2,S 
Antidepressants  Fluoxetine N06AB03 A1 
Antidepressants  Citalopram N06AB04 A1 
Antidepressants  Fluvoxamine N06AB08 A1 
Antidepressants  Trazodone N06AX05 A1 
Antidepressants  Mirtazapine N06AX11 A1,S 
Opioid dependence Methadone N07BC02 A1 
Obstructive airway diseases Ipratropium R03BB01 A2 
Obstructive airway diseases Theophylline R03DA04 A1 
Cough suppressants opium Codeine R05DA04 A1 
Antihistamines Dimenhydrinate R06AA52 A2 
Antihistamines Diphenhydramine R06AA02 A2 
Antihistamines Brompheniramine R06AB01 A2 
Antihistamines Dexchlorpheniramine R06AB02 A2 
Antihistamines Chlorphenamine R06AB04 A2 
Antihistamines Pyrilamine R06AC01 A2 
Antihistamines Alimemazine R06AD01 A1 
Antihistamines Promethazine R06AD02 A2,S 
Antihistamines Cetirizine R06AE07 A1 
Antihistamines Loratadine R06AX13 A1 
Antihistamines Fexofenadine R06AX26 A1 
 
Appendix 3: Medicines accounting for the difference between PIMcog list and the list of 
anticholinergic and sedative agents 
Medicines on the list of anticholinergics 
and sedatives only 
Medicines on the PIMcog list only 
 
Name ATC Effect Name ATC 
Dicyclomine A03AA07 A2 Famotidine A02BA03 
Domperidone A03FA03 A1 Hyoscyamine products A03BA03 
Methyldopa C02AB01 S Betamethasone H02AB01 
Ketorolac M01AB15 A1 Dexamethasone H02AB02 
Methocarbamol M03BA03 A1 Methylprednisolone H02AB04 
Baclofen M03BX01 A1,S Prednisolone/prednisone H02AB06 
Morphine N02AA01 A1,S Triamcinolone H02AB08 
Codeine/paracetamol N02AA59 S Hydrocortisone H02AB09 
Fentanyl N02AB03 A1,S Loxapine N05AH01 
Dextropropoxyphene N02AC04 S Midazolam N05CD08 
Tramadol N02AX02 A1,S Betamethasone R03BA04 
Phenytoin N03AB02 S Dexbrompheniramine R06AB06 
Clonazepam N03AE01 A1,S Triprolidine R06AX07 
Carbamazepine N03AF01 A1,S 
  Oxcarbazepine N03AF02 A1 
  Valproate N03AG01 S 
  Vigabatrin N03AG04 S 
  Lamotrigine N03AX09 S 
  Topiramate N03AX11 S 
  Gabapentin N03AX12 S 
  Pregabalin N03AX16 S 
  Entacapone N04BX02 A1 
  Levomepromazine N05AA02 A2 
  Haloperidol N05AD01 A1,S 




  Amisulpride N05AL05 S 
  Lithium N05AN01 A1 
  Risperidone N05AX08 A1,S 
  Chlordiazepoxide N05BA02 A1 
  Bromazepam N05BA08 S 
  Fluoxetine N06AB03 A1 
  Citalopram N06AB04 A1 
  Fluvoxamine N06AB08 A1 
  Trazodone N06AX05 A1 
  Mirtazapine N06AX11 A1,S 
  Methadone N07BC02 A1 
  Ipratropium R03BB01 A2 
  Theophylline R03DA04 A1 
  
Codeine R05DA04 A1 
  Pyrilamine R06AC01 A2 
  Alimemazine R06AD01 A1 
  Cetirizine R06AE07 A1 
  Fexofenadine R06AX26 A1 
  
 
